Nevanac (Nepafenac)

Nepafenac, the active ingredient in Nevanac, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an ophthalmic suspension for ocular use. It is indicated for the treatment of post‑operative ocular inflammation and pain following cataract surgery.

GNH USA supplies Nevanac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nevanac (nepafenac) is used to manage inflammation and pain in the postoperative ocular setting.

- Post‑operative ocular inflammation: reduces inflammatory response after eye surgery. - Pain following cataract surgery: alleviates discomfort after cataract extraction. - General ocular pain: provides relief after various eye procedures.

Common Side Effects: - Burning or stinging sensation on instillation. - Transient ocular itching. - Foreign body sensation. - Temporary blurred vision. - Conjunctival hyperemia. - Mild eye discomfort.

Serious or Rare Side Effects: - Corneal ulceration or epithelial defect. - Significant increase in intra‑ocular pressure. - Severe allergic reaction (e.g., angio‑edema, anaphylaxis). - Persistent or worsening eye pain. - Vision loss or marked visual acuity reduction. - Endophthalmitis.

Before using Nevanac, consider the following precautions: - Assess ocular infection: ensure no active bacterial, viral, or fungal infection before initiation. - Monitor intra‑ocular pressure: watch for elevations, especially in glaucoma patients. - Avoid concurrent ocular NSAIDs: combined use may increase toxicity. - Use with caution in corneal disorders: patients with epithelial defects may be at higher risk. - Store at room temperature: keep in the original container, protect from light and moisture.

Nevanac may interact with other ophthalmic or systemic agents.

Major Interactions (Avoid): - Concurrent use with other ophthalmic NSAIDs: additive toxicity to corneal epithelium. - Co‑administration with corticosteroid eye drops: may delay wound healing. - Use with prostaglandin analogs for glaucoma: potential reduction in IOP‑lowering effect.

Moderate Interactions (Monitor Closely): - Systemic NSAIDs: increased overall NSAID load may raise bleeding risk. - Anticoagulants or antiplatelet agents: monitor for ocular bleeding after surgery. - Contact lens wear: may affect drug distribution and comfort.